Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
Academic Journal
The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin therapy is more effective than placebo in controlling glycemic level, glucagon-like peptide (GLP-1) are associated with weight loss and dipeptidyl peptidase (DDP4) inhibitors are linked with weight gain.


Related Articles

  • COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes. Vella, Adrian // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are...

  • Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Riddle, Matthew C.; Drucker, Daniel J. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p435 

    Discusses a study which summarized several limitations in the treatment of type 2 diabetes and describes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Barriers to...

  • Glucagon-like peptide agonists. Gadsby, Roger // Practice Nurse;4/9/2010, Vol. 39 Issue 7, p30 

    The article discusses glucagon-like peptide 1 (GLP-1) and its potential role in the treatment of type 2 diabetes. The levels of GLP-1 in people with diabetes are reduced in response to a meal and it is easily broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Clinical tests reveal that...

  • Gliptins: A New Class of Oral Antidiabetic Agents. SESHADRI, K. G.; KIRUBHA, M. H. B. // Indian Journal of Pharmaceutical Sciences;2009, Vol. 71 Issue 6, p608 

    India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for...

  • Nonlinear Increase in GLP-1 Levels in Response to DPP-IV Inhibition in Healthy Adult Subjects. Dai, Haiqinq; Gustavson, Stephanie M.; Calle, Roberto A.; Hirshberg, Boaz // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Dipeptidyl Peptidase IV (DPP-IV) inhibitors represent a new promising target for the treatment of T2DM. The aim of this study was to investigate the effects of DPP-IV inhibition by PF-00734200, a potent competitive DPP-IV inhibitor, on the dynamics of plasma in healthy adult subjects. In a...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • A gut-heart connection in cardiometabolic regulation. Buglioni, Alessia; Burnett, John C // Nature Medicine;May2013, Vol. 19 Issue 5, p534 

    The article offers information on the study of Kim and colleagues which examines the link between glucagon-like peptide-1 (GLP-1) release from the cardiac hormone atrial natriuretic peptide and gut. It states that glycemia in patients with type 2 diabetes were controlled using GLP-1 receptor...

  • Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Dave, Darshan J. // Journal of Pharmacology & Pharmacotherapeutics;Oct2011, Vol. 2 Issue 4, p230 

    Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin defi ciency or resistance. Management starts with single oral antidiabetic drug (OAD) but eventually switch over to combination therapy because of progressive ?-cell dysfunction. Hypoglycemia, weight gain, and...

  • Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Feng, Ping; Yu, De-min; Chen, Li-ming; Chang, Bao-cheng; Ji, Qiu-di; Li, Shu-ying; Zhu, Mei; Ding, Sheng-hua; Zhang, Bao-zhen; Wang, Su-li; Li, Hong-tao; Lin, Jing-na; Wang, Mao-jun; Guo, Jian-chao; Liu, Jie; Liu, Zhong-dong; Wu, Shen-tao; Yang, Ju-hong // Acta Pharmacologica Sinica;Feb2015, Vol. 36 Issue 2, p200 

    Aim:To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.Methods:A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics